Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $38.00 at Needham & Company LLC

Viridian Therapeutics (NASDAQ:VRDN) had its price target lifted by research analysts at Needham & Company LLC from $30.00 to $38.00 in a note issued to investors on Wednesday, Marketbeat reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s target price would indicate a potential upside of 83.57% from the stock’s previous close.

VRDN has been the topic of a number of other reports. Oppenheimer restated an “outperform” rating and issued a $28.00 target price (down from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. BTIG Research raised their target price on shares of Viridian Therapeutics from $46.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday. The Goldman Sachs Group assumed coverage on shares of Viridian Therapeutics in a research note on Thursday, June 6th. They issued a “buy” rating and a $23.00 target price for the company. Wolfe Research started coverage on Viridian Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $29.00 price target on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, August 28th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Viridian Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.91.

Viridian Therapeutics Trading Up 4.5 %

Shares of VRDN opened at $20.70 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 15.82 and a quick ratio of 15.82. Viridian Therapeutics has a 1-year low of $10.93 and a 1-year high of $24.18. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -4.60 and a beta of 1.03. The firm has a 50 day simple moving average of $15.20 and a 200-day simple moving average of $15.03.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). Viridian Therapeutics had a negative return on equity of 83.18% and a negative net margin of 79,185.77%. The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.09 million. Equities analysts forecast that Viridian Therapeutics will post -3.97 EPS for the current fiscal year.

Hedge Funds Weigh In On Viridian Therapeutics

A number of large investors have recently modified their holdings of VRDN. Quest Partners LLC increased its position in Viridian Therapeutics by 344.0% during the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock worth $79,000 after purchasing an additional 4,692 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Viridian Therapeutics by 19.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after acquiring an additional 799 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Viridian Therapeutics by 24.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after acquiring an additional 2,359 shares in the last quarter. AlphaCentric Advisors LLC boosted its position in Viridian Therapeutics by 108.3% during the 2nd quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock worth $163,000 after purchasing an additional 6,500 shares during the period. Finally, Arizona State Retirement System increased its holdings in Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after purchasing an additional 1,688 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.